Treating Patients with Complex Metabolic Conditions


Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.


Year Invested: 2011
Location: Newton, Mass.
Visit: www.allenapharma.com

Recent News

March 27, 2018
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

March 7, 2018
Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference

March 6, 2018
Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner